All Updates

All Updates

icon
Filter
Funding
Cellino Biotech raises USD 80 million in Series A
AI Drug Discovery
Jan 25, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Jan 25, 2022

Cellino Biotech raises USD 80 million in Series A

Funding

  • Massachusetts-based AI cell therapy company Cellino Biotech has raised USD 80 million in a Series A funding round led by Leaps by Bayer (the impact investment arm of Bayer AG) and Humboldt Fund. Among others, existing investor Khosla Ventures and new investor Felicis Ventures also participated in the round. 

  • The proceeds will be directed toward advancing its AI-based platform with improved machine learning and hardware capabilities to offer both autologous (using patient’s own cells) and allogeneic (using donor cells) therapies. The company also plans to build a good manufacturing practices (GMP) standard facility to assist in clinical trials. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.